Traveler’s Diarrhea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major traveler’s diarrhea markets are expected to exhibit a CAGR of 5.31% during 2024-2034.
The traveler’s diarrhea market has been comprehensively analyzed in IMARC's new report titled "Traveler’s Diarrhea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Traveler's diarrhea is a type of unpleasant gastrointestinal infection that occurs upon the consumption of contaminated food or water during travel. It is most caused by the E. coli bacteria, but can also be developed by other organisms, like viruses and parasites. The symptoms of this condition usually include abdominal cramps and pain, nausea, vomiting, sudden onset of the passage of more than two watery stools a day, bloating, loss of appetite, urgent and frequent bowel movements, etc. In severe cases, individuals suffering from the ailment may also experience dehydration, dry mouth, fatigue, weakness, blood in the stool, headaches, dizziness, and electrolyte imbalances. The diagnosis of this illness is mainly based on the identification of the patient's indications and comprehensive travel history. Several medical exams and laboratory tests are performed to check a person's overall health and rule out any further diseases that could be causing the symptoms. The healthcare provider may also conduct stool cultures and polymerase chain reaction (PCR) tests to validate the diagnosis among patients.
The increasing cases of viral, bacterial, and parasitic infections on account of poor public hygiene, resulting in contaminated food or water, are primarily driving the traveler's diarrhea market. In addition to this, the rising incidences of several associated risk factors, such as young adult tourists, unhealthy dietary choices, a weakened immune system, etc., are also bolstering the market growth. Furthermore, the widespread adoption of antimotility agents, involving loperamide and diphenoxylate, for managing disease symptoms by controlling gastrointestinal muscle spasms and reducing the frequency of bowel movements is acting as another significant growth-inducing factor. Additionally, the growing application of lifestyle modifications, which include the consumption of a BRAT (bananas, rice, applesauce, and toast) diet that helps in easing stomach distress as well as preventing dehydration in patients, is further augmenting the market growth. Apart from this, the emerging popularity of oral hydration formulas, since they can optimize fluid absorption in the intestines, thereby quickly replenishing electrolytes in the body, is expected to drive the traveler's diarrhea market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the traveler’s diarrhea market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for traveler’s diarrhea and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the traveler’s diarrhea market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the traveler’s diarrhea market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the traveler’s diarrhea market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current traveler’s diarrhea marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the traveler’s diarrhea market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the traveler’s diarrhea market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the traveler’s diarrhea market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of traveler’s diarrhea across the seven major markets?
What is the number of prevalent cases (2018-2034) of traveler’s diarrhea by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of traveler’s diarrhea by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with traveler’s diarrhea across the seven major markets?
What is the size of the traveler’s diarrhea patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of traveler’s diarrhea?
What will be the growth rate of patients across the seven major markets?
Traveler’s Diarrhea: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for traveler’s diarrhea drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the traveler’s diarrhea market?
What are the key regulatory events related to the traveler’s diarrhea market?
What is the structure of clinical trial landscape by status related to the traveler’s diarrhea market?
What is the structure of clinical trial landscape by phase related to the traveler’s diarrhea market?
What is the structure of clinical trial landscape by route of administration related to the traveler’s diarrhea market?
The traveler’s diarrhea market has been comprehensively analyzed in IMARC's new report titled "Traveler’s Diarrhea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Traveler's diarrhea is a type of unpleasant gastrointestinal infection that occurs upon the consumption of contaminated food or water during travel. It is most caused by the E. coli bacteria, but can also be developed by other organisms, like viruses and parasites. The symptoms of this condition usually include abdominal cramps and pain, nausea, vomiting, sudden onset of the passage of more than two watery stools a day, bloating, loss of appetite, urgent and frequent bowel movements, etc. In severe cases, individuals suffering from the ailment may also experience dehydration, dry mouth, fatigue, weakness, blood in the stool, headaches, dizziness, and electrolyte imbalances. The diagnosis of this illness is mainly based on the identification of the patient's indications and comprehensive travel history. Several medical exams and laboratory tests are performed to check a person's overall health and rule out any further diseases that could be causing the symptoms. The healthcare provider may also conduct stool cultures and polymerase chain reaction (PCR) tests to validate the diagnosis among patients.
The increasing cases of viral, bacterial, and parasitic infections on account of poor public hygiene, resulting in contaminated food or water, are primarily driving the traveler's diarrhea market. In addition to this, the rising incidences of several associated risk factors, such as young adult tourists, unhealthy dietary choices, a weakened immune system, etc., are also bolstering the market growth. Furthermore, the widespread adoption of antimotility agents, involving loperamide and diphenoxylate, for managing disease symptoms by controlling gastrointestinal muscle spasms and reducing the frequency of bowel movements is acting as another significant growth-inducing factor. Additionally, the growing application of lifestyle modifications, which include the consumption of a BRAT (bananas, rice, applesauce, and toast) diet that helps in easing stomach distress as well as preventing dehydration in patients, is further augmenting the market growth. Apart from this, the emerging popularity of oral hydration formulas, since they can optimize fluid absorption in the intestines, thereby quickly replenishing electrolytes in the body, is expected to drive the traveler's diarrhea market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the traveler’s diarrhea market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for traveler’s diarrhea and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the traveler’s diarrhea market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the traveler’s diarrhea market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the traveler’s diarrhea market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current traveler’s diarrhea marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the traveler’s diarrhea market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the traveler’s diarrhea market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the traveler’s diarrhea market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of traveler’s diarrhea across the seven major markets?
What is the number of prevalent cases (2018-2034) of traveler’s diarrhea by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of traveler’s diarrhea by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with traveler’s diarrhea across the seven major markets?
What is the size of the traveler’s diarrhea patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of traveler’s diarrhea?
What will be the growth rate of patients across the seven major markets?
Traveler’s Diarrhea: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for traveler’s diarrhea drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the traveler’s diarrhea market?
What are the key regulatory events related to the traveler’s diarrhea market?
What is the structure of clinical trial landscape by status related to the traveler’s diarrhea market?
What is the structure of clinical trial landscape by phase related to the traveler’s diarrhea market?
What is the structure of clinical trial landscape by route of administration related to the traveler’s diarrhea market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 TRAVELER’S DIARRHEA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 TRAVELER’S DIARRHEA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 TRAVELER’S DIARRHEA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 TRAVELER’S DIARRHEA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 TRAVELER’S DIARRHEA - UNMET NEEDS
10 TRAVELER’S DIARRHEA - KEY ENDPOINTS OF TREATMENT
11 TRAVELER’S DIARRHEA - MARKETED PRODUCTS
11.1 List of Traveler’s Diarrhea Marketed Drugs Across the Top 7 Markets
11.1.1 Aemcolo (Rifamycin controlled-release) - Cosmo/Dr Falk Pharma/Salix
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Xifaxan (Rifaximin) - Alfasigma
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 TRAVELER’S DIARRHEA - PIPELINE DRUGS
12.1 List of Traveler’s Diarrhea Pipeline Drugs Across the Top 7 Markets
12.1.1 Etvax - Scandinavian Biopharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Campylobacter jejuni/Escherichia coli oral vaccine - Immuron
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. TRAVELER’S DIARRHEA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. TRAVELER’S DIARRHEA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 TRAVELER’S DIARRHEA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Traveler’s Diarrhea - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Traveler’s Diarrhea - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Traveler’s Diarrhea - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Traveler’s Diarrhea - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Traveler’s Diarrhea - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Traveler’s Diarrhea - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Traveler’s Diarrhea - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Traveler’s Diarrhea - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Traveler’s Diarrhea - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Traveler’s Diarrhea - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Traveler’s Diarrhea - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Traveler’s Diarrhea - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Traveler’s Diarrhea - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Traveler’s Diarrhea - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Traveler’s Diarrhea - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Traveler’s Diarrhea - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Traveler’s Diarrhea - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Traveler’s Diarrhea - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Traveler’s Diarrhea - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Traveler’s Diarrhea - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Traveler’s Diarrhea - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Traveler’s Diarrhea - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Traveler’s Diarrhea - Access and Reimbursement Overview
16 TRAVELER’S DIARRHEA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 TRAVELER’S DIARRHEA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 TRAVELER’S DIARRHEA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 TRAVELER’S DIARRHEA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 TRAVELER’S DIARRHEA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 TRAVELER’S DIARRHEA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 TRAVELER’S DIARRHEA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 TRAVELER’S DIARRHEA - UNMET NEEDS
10 TRAVELER’S DIARRHEA - KEY ENDPOINTS OF TREATMENT
11 TRAVELER’S DIARRHEA - MARKETED PRODUCTS
11.1 List of Traveler’s Diarrhea Marketed Drugs Across the Top 7 Markets
11.1.1 Aemcolo (Rifamycin controlled-release) - Cosmo/Dr Falk Pharma/Salix
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Xifaxan (Rifaximin) - Alfasigma
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 TRAVELER’S DIARRHEA - PIPELINE DRUGS
12.1 List of Traveler’s Diarrhea Pipeline Drugs Across the Top 7 Markets
12.1.1 Etvax - Scandinavian Biopharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Campylobacter jejuni/Escherichia coli oral vaccine - Immuron
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. TRAVELER’S DIARRHEA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. TRAVELER’S DIARRHEA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 TRAVELER’S DIARRHEA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Traveler’s Diarrhea - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Traveler’s Diarrhea - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Traveler’s Diarrhea - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Traveler’s Diarrhea - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Traveler’s Diarrhea - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Traveler’s Diarrhea - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Traveler’s Diarrhea - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Traveler’s Diarrhea - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Traveler’s Diarrhea - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Traveler’s Diarrhea - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Traveler’s Diarrhea - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Traveler’s Diarrhea - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Traveler’s Diarrhea - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Traveler’s Diarrhea - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Traveler’s Diarrhea - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Traveler’s Diarrhea - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Traveler’s Diarrhea - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Traveler’s Diarrhea - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Traveler’s Diarrhea - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Traveler’s Diarrhea - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Traveler’s Diarrhea - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Traveler’s Diarrhea - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Traveler’s Diarrhea - Access and Reimbursement Overview
16 TRAVELER’S DIARRHEA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 TRAVELER’S DIARRHEA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 TRAVELER’S DIARRHEA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
